HIF-1α suppressing small molecule, LW6, inhibits cancer cell growth by binding to calcineurin b homologous protein 1

Hypoxia inducible factor-1 alpha (HIF-1α) plays an important role in angiogenesis and metastasis and is a promising therapeutic target for the development of anti-cancer drugs. We recently developed a new synthetic small molecule inhibitor of HIF-1α, LW6, which results in inhibition of angiogenesis . To investigate its underlying mechanism, target protein identification was conducted by reverse chemical proteomics using phage display . We identified calcineurin b homologous protein 1 (CHP1) as a target protein of LW6, which specifically binds to CHP1 in a Ca 2+ dependent manner. Covalent labeling of LW6 using photoaffinity and click chemistry demonstrated its co-localization with CHP1 in live cells. HIF-1α was decreased by CHP1 knockdown in HepG2 cells, and angiogenesis was not induced in HUVEC cells by treatment with conditioned media from CHP1 knockdown cells compared to the control. These data demonstrated that LW6 inhibited HIF-1α stability via direct binding with CHP1 resulting in suppression of angiogenesis, providing a new insight into the role of CHP1 in HIF-1α regulation. LW6 could serve as a new chemical probe to explore CHP1 function. • Target protein identification of LW6, a new synthetic small molecule inhibiting HIF-1α, was conducted by phage display biopanning. • LW6 specifically binds to the calcineurin b homologous protein 1 in calcium-dependent manner. • HIF-1α was decreased by CHP1 knockdown in HepG2 cells. • LW6 inhibits HIF-1α stability via direct binding with CHP1 resulted in suppression of angiogenesis.